{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:50:14Z","timestamp":1793998214302,"version":"4.8.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1111\/j.1365-2133.2010.09863.x","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T22:45:01Z","timestamp":1274913901000},"page":"847-853","source":"Crossref","is-referenced-by-count":221,"title":["Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.1093","volume":"163","author":[{"given":"L.","family":"Valeyrie-Allanore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Brochard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ma\u00eetre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Revuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Roujeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,5,25]]},"reference":[{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB5|cit5","first-page":"473","volume-title":"Braun-Falco\u2019s Dermatology","author":"Mockenhaupt","year":"2008"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hopitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects","volume":"25","author":"Heng","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.1997.tb01044.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor","volume":"22","author":"Jarrett","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.1995.tb02649.x","article-title":"Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin","volume":"133","author":"Zaki","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1440-0960.1996.tb01057.x","article-title":"Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management","volume":"37","author":"Sullivan","year":"1996","journal-title":"Australas J Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/0378-6323.41379","article-title":"Suprapharmacological doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis","volume":"74","author":"Rai","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB25|cit25","first-page":"31","article-title":"Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF","volume":"32","author":"Robak","year":"2001","journal-title":"J Med"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporine A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in TEN: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1006\/bbrc.1997.6658","article-title":"Cyclosporin A-sensitive calcium signaling represses NF-kappaB activation in human bronchial epithelial cells and enhances NF-kappaB activation in Jurkat T-cells","volume":"234","author":"Aoki","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2230.1992.tb02163.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin","volume":"17","author":"Hewitt","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00234-004-1256-5","article-title":"Reversible encephalopathy syndrome: report of 12 cases with follow-up","volume":"46","author":"Greco Crasto","year":"2004","journal-title":"Neuroradiology"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB31|cit31","first-page":"205","article-title":"Clinical spectrum of reversible posterior leukoencephalopathy syndrome","volume":"65","author":"Lee","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB32|cit32","first-page":"163","article-title":"Chemotherapy-related posterior reversible leukoencephalopathy syndrome","volume":"5","author":"Bhatt","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB33|cit33","first-page":"577","article-title":"Risk factors for development of hypomagnesemia in the burned patient","volume":"140","author":"Dur\u00e1n-Vega","year":"2004","journal-title":"Gac Med Mex"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Carrotto","year":"2008","journal-title":"J Burn Care Res"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"TEN: analysis of clinical course and SCORTEN based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.BCR.0000216532.71360.9B","article-title":"SCORTEN overestimates mortality in the setting of a standardized treatment protocol","volume":"27","author":"Imahara","year":"2006","journal-title":"J Burn Care Res"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2010.09863.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2010.09863.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2010.09863.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2010.09863.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T21:40:15Z","timestamp":1711489215000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/163\/4\/847\/6644121"}},"subtitle":["Ciclosporin for SJS and TEN"],"short-title":[],"issued":{"date-parts":[[2010,5,25]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09863.x","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5,25]]}}}